Is Alcon (ALC) Stock Outpacing Its Medical Peers This Year?
Here is how Alcon (ALC) and Anavex Life Sciences (AVXL) have performed compared to their sector so far this year.
Why Alcon (ALC) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Alcon's Q4 Earnings Miss Estimates, Stock Falls, Revenues Rise Y/Y
ALC's Q4 EPS and revenues lag estimates, sending shares down 3%, even as sales increase 9% and 2026 guidance targets up to 7% growth.
Eye-care group Alcon expects product launches to drive 2026 sales, profitability
Alcon on Tuesday forecast 2026 sales growth largely in line with market estimates and guided for a significant expansion in its operating margin, signalling confidence that product launches would drive improved profitability.
Alcon (ALC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Alcon (ALC) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Alcon Inc. (ALC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Alcon Inc. (ALC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Alcon lifts bid for medical technology firm Staar to $1.6 billion
Swiss eyecare giant Alcon has lifted its bid to acquire Staar Surgical to $30.75 per share in cash, it said on Tuesday, valuing the medical technology firm at $1.6 billion.
Alcon: Some Premium Coming Out Of This Quality Play
Alcon Inc. remains a global leader in eye care, benefiting from aging demographics and technological innovation, but faces valuation and growth headwinds. Recent M&A activity, including the pending STAAR Surgical deal, pressures near-term earnings and adds uncertainty, despite strategic fit. ALC shares have declined from highs, now trading at a more reasonable 25 times earnings, but growth is slowing, and valuation remains somewhat elevated.
ALC's Q3 Earnings Beat, Revenues Miss, Stock Rises in After-Market Hours
Alcon posts mixed Q3 results as earnings top estimates but revenues miss; new product launches fuel optimism.
Alcon (ALC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Alcon (ALC) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Curious about Alcon (ALC) Q3 Performance? Explore Wall Street Estimates for Key Metrics
Evaluate the expected performance of Alcon (ALC) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
ALC or ISRG: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Instruments stocks have likely encountered both Alcon (ALC) and Intuitive Surgical, Inc. (ISRG). But which of these two stocks offers value investors a better bang for their buck right now?
